Minimal Residual Disease Testing Market Size | Report 2032

Minimal Residual Disease Testing Market - By Technology (Flow-cytometry, Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS)), By Application (Lymphoma, Leukemia, Solid Tumors), By End-use, & Forecast, 2023 – 2032 

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology &amp; Scope

1.1&nbsp;&nbsp;&nbsp; Industry coverage

1.2&nbsp;&nbsp;&nbsp; Market scope &amp; definition

1.3&nbsp;&nbsp;&nbsp; Base estimates &amp; calculations

1.3.1&nbsp;&nbsp;&nbsp; Data collection

1.4&nbsp;&nbsp;&nbsp; Forecast parameters

1.5&nbsp;&nbsp;&nbsp; COVID-19 impact analysis at global level

1.6&nbsp;&nbsp;&nbsp; Data validation

1.7&nbsp;&nbsp;&nbsp; Data Sources

1.7.1&nbsp;&nbsp;&nbsp; Primary

1.7.2&nbsp;&nbsp;&nbsp; Secondary

1.7.2.1&nbsp;&nbsp;&nbsp;Paid sources

1.7.2.2&nbsp;&nbsp;&nbsp;Unpaid sources

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Minimal residual disease testing industry 3600&nbsp;synopsis, 2018 &ndash; 2032

2.2&nbsp;&nbsp;&nbsp; Business trends

2.3&nbsp;&nbsp;&nbsp; Regional trends

2.4&nbsp;&nbsp;&nbsp; Technology trends

2.5&nbsp;&nbsp;&nbsp; Application trends

2.6&nbsp;&nbsp;&nbsp; End-use trends

Chapter 3&nbsp;&nbsp;&nbsp;Minimal Residual Disease Testing Industry Insights

3.1&nbsp;&nbsp;&nbsp; Industry ecosystem analysis

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp;Increasing prevalence of cancer

3.2.1.2&nbsp;&nbsp;&nbsp;Technological advancements

3.2.1.3&nbsp;&nbsp;&nbsp;Rising investment in R&amp;D activities

3.2.1.4&nbsp;&nbsp;&nbsp;Diagnostic advantages in minimal residual disease testing

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls &amp; challenges

3.2.2.1&nbsp;&nbsp;&nbsp;Stringent regulatory policies

3.2.2.2&nbsp;&nbsp;&nbsp;High cost of minimal residual disease testing

3.3&nbsp;&nbsp;&nbsp; Growth potential analysis

3.3.1&nbsp;&nbsp;&nbsp; By technology

3.3.2&nbsp;&nbsp;&nbsp; By application

3.3.4&nbsp;&nbsp;&nbsp; By end use

3.4&nbsp;&nbsp;&nbsp; COVID- 19 impact analysis

3.5&nbsp;&nbsp;&nbsp; Pricing analysis, 2022

3.6&nbsp;&nbsp;&nbsp; Regulatory landscape

3.6.1&nbsp;&nbsp;&nbsp; U.S.

3.6.2&nbsp;&nbsp;&nbsp; Europe

3.7&nbsp;&nbsp;&nbsp; Technology landscape

3.8&nbsp;&nbsp;&nbsp; Reimbursement scenario

3.9&nbsp;&nbsp;&nbsp; Future market trends

3.10&nbsp;&nbsp;&nbsp; Gap analysis

3.11&nbsp;&nbsp;&nbsp; Porter&#39;s analysis

3.12&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2022

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company matrix analysis, 2022

4.3&nbsp;&nbsp;&nbsp; Company market share analysis, 2022

4.4&nbsp;&nbsp;&nbsp; Competitive positioning matrix

4.5&nbsp;&nbsp;&nbsp; Vendor matrix analysis, 2022

4.6&nbsp;&nbsp;&nbsp; Strategy dashboard, 2022

Chapter 5&nbsp;&nbsp;&nbsp;Minimal Residual Disease Testing Market Size and Forecast, By Technology (USD Million &amp; Units)

5.1&nbsp;&nbsp;&nbsp; Key trends, by technology

5.2&nbsp;&nbsp;&nbsp; Flow-cytometry

5.3&nbsp;&nbsp;&nbsp; Polymerase chain reaction (PCR)

5.4&nbsp;&nbsp;&nbsp; Next generation sequencing (NGS)

5.5&nbsp;&nbsp;&nbsp; Others

Chapter 6&nbsp;&nbsp;&nbsp;Minimal Residual Disease Testing Market Size and Forecast, By Application (USD Million)

6.1&nbsp;&nbsp;&nbsp; Key trends, by application

6.2&nbsp;&nbsp;&nbsp; Lymphoma

6.3&nbsp;&nbsp;&nbsp; Leukemia

6.4&nbsp;&nbsp;&nbsp; Solid Tumors

6.5&nbsp;&nbsp;&nbsp; Others

Chapter 7&nbsp;&nbsp;&nbsp;Minimal Residual Disease Testing Market Size and Forecast, By End-use (USD Million)

7.1&nbsp;&nbsp;&nbsp; Key trends, by end-use

7.2&nbsp;&nbsp;&nbsp; Hospitals

7.3&nbsp;&nbsp;&nbsp; Specialty clinics

7.4&nbsp;&nbsp;&nbsp; Diagnostic centers

7.5&nbsp;&nbsp;&nbsp; Others

Chapter 8&nbsp;&nbsp;&nbsp;Minimal Residual Disease Testing Market Size and Forecast, By Region (USD Million)

8.1&nbsp;&nbsp;&nbsp; Key trends, by region

8.2&nbsp;&nbsp;&nbsp; North America

8.2.1&nbsp;&nbsp;&nbsp; U.S.

8.2.2&nbsp;&nbsp;&nbsp; Canada

8.3&nbsp;&nbsp;&nbsp; Europe

8.3.1&nbsp;&nbsp;&nbsp; Germany

8.3.2&nbsp;&nbsp;&nbsp; UK

8.3.3&nbsp;&nbsp;&nbsp; France

8.3.4&nbsp;&nbsp;&nbsp; Spain

8.3.5&nbsp;&nbsp;&nbsp; Italy

8.3.6&nbsp;&nbsp;&nbsp; Poland

8.3.7&nbsp;&nbsp;&nbsp; Sweden

8.3.8&nbsp;&nbsp;&nbsp; The Netherlands

8.4&nbsp;&nbsp;&nbsp; Asia Pacific

8.4.1&nbsp;&nbsp;&nbsp; Japan

8.4.2&nbsp;&nbsp;&nbsp; China

8.4.3&nbsp;&nbsp;&nbsp; India

8.4.4&nbsp;&nbsp;&nbsp; Australia

8.4.5&nbsp;&nbsp;&nbsp; South Korea

8.4.6&nbsp;&nbsp;&nbsp; Thailand

8.4.7&nbsp;&nbsp;&nbsp; Indonesia

8.4.8&nbsp;&nbsp;&nbsp; Philippines

8.5&nbsp;&nbsp;&nbsp; Latin America

8.5.1&nbsp;&nbsp;&nbsp; Brazil

8.5.2&nbsp;&nbsp;&nbsp; Mexico

8.5.3&nbsp;&nbsp;&nbsp; Argentina

8.5.4&nbsp;&nbsp;&nbsp; Columbia

8.5.5&nbsp;&nbsp;&nbsp; Chile

8.5.6&nbsp;&nbsp;&nbsp; Peru

8.6&nbsp;&nbsp;&nbsp; MEA

8.6.1&nbsp;&nbsp;&nbsp; South Africa

8.6.2&nbsp;&nbsp;&nbsp; Saudi Arabia

8.6.3&nbsp;&nbsp;&nbsp; UAE

8.6.4&nbsp;&nbsp;&nbsp; Israel

8.6.5&nbsp;&nbsp;&nbsp; Turkey

8.6.6&nbsp;&nbsp;&nbsp; Iran

Chapter 9&nbsp;&nbsp;&nbsp;Company Profiles

9.1&nbsp;&nbsp;&nbsp; Adaptive Biotechnologies

9.2&nbsp;&nbsp;&nbsp; Amgen Inc.

9.3&nbsp;&nbsp;&nbsp; AstraZeneca

9.4&nbsp;&nbsp;&nbsp; Bio-Rad Laboratories

9.5&nbsp;&nbsp;&nbsp; Bio-Techne

9.6&nbsp;&nbsp;&nbsp; Bristol-Myers Squibb Company

9.7&nbsp;&nbsp;&nbsp; Exact Sciences Corporation

9.8&nbsp;&nbsp;&nbsp; Guardant Health

9.9&nbsp;&nbsp;&nbsp; Invitae

9.10&nbsp;&nbsp;&nbsp; iRepertoire

9.11&nbsp;&nbsp;&nbsp; Kite Pharma

9.12&nbsp;&nbsp;&nbsp; mdxhealth

9.13&nbsp;&nbsp;&nbsp; Natera, Inc.

9.14&nbsp;&nbsp;&nbsp; Navidea Biopharmaceuticals

9.15&nbsp;&nbsp;&nbsp; NeoGenomics Laboratories

9.16&nbsp;&nbsp;&nbsp; Novartis

9.17&nbsp;&nbsp;&nbsp; Personalis

9.18&nbsp;&nbsp;&nbsp; QIAGEN

9.19&nbsp;&nbsp;&nbsp; Roche

9.20&nbsp;&nbsp;&nbsp; Sysmex Corporation

9.21&nbsp;&nbsp;&nbsp; Veracyte, Inc. 
&nbsp;

Minimal Residual Disease Testing Market

Customize This Report